Vis børsmeldingen
Jostein Dahle, will give a presentation on 9 March at the 11[th] Annual World
ADC Europe 2021 Digital (https://worldadc-europe.com/) event (8-11 March 2021)
in the Discovery stream discussing the question: Should Payloads be Super
-Potent?
Presentation details are as follows:
Title: Targeting CD37 with Alpha- & Beta-Emitting Radioimmunoconjugates
Date/time: Tuesday, 9 March 2021 at 11:40am GMT
During his presentation, Dr Dahle with cover the following points:
· Review CD37 as target for radioimmunotherapy
· Analyse preclinical and clinical data for treatment of Non-Hodgkin’s
Lymphoma (NHL) with the beta-emitting radioimmunoconjugate [177]Lu-lilotomab
satetraxetan (Betalutin®)
· Evaluate preclinical data for treatment of Chronic Lymphocytic Leukaemia and
NHL with the alpha-emitting radioimmunoconjugate [212]Pb-TCMC-NNV003 (Alpha37)
World ADC Europe is an industry-leading conference and Europe’s largest
gathering of ADC stakeholders. It brings together 300 drug developers from 160
active ADC organisations to help forward-thinking researchers from the
pharmaceutical, biotech and academic community advance the development of
antibody-drug conjugates.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
Kilde